12
BI201335 combined with peg-interferon alfa-2a and ribavirin (PR) in treatment-naïve patients with chronic genotype-1 HCV infection: Results of the SILEN-C3 trial
Treatment for 12 or 24 weeks with BI201335 combined with peg-interferon alfa-2a and ribavirin (PR) in
treatment-naïve patients with chronic genotype-1 HCV infection:
Results of the SILEN-C3 trial
SILEN-C3 trial
Main inclusion criteria
Baseline characteristics
Virologic response
Treatment outcome
Time to undetectable HCV RNAcorrelated with SVR
Adverse events: overall summary
Most common adverse events (>15% in any group)
Summary
Acknowledgements
